

XBiotech Inc.  
Form 8-K  
July 29, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) July 28, 2015**

---

**XBIOTECH INC.**

**(Exact name of registrant as specified in its charter)**

---

**British Columbia, Canada**

(State of Incorporation)

**001-37347**

(Commission File Number)

N/A

**8201 E Riverside Dr. Bldg 4, Ste 100  
Austin, Texas**

(Address of principal executive offices)

**78744**

(Zip Code)

**(512) 386-2900**

(Registrant's telephone number, including area code)

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02. Results of Operations and Financial Condition.**

On July 28, 2015, XBiotech Inc. (the "Company"), issued a press release providing a second quarter 2015 corporate and clinical update, which included an update on its cash position as of June 30, 2015. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On July 28, 2015, XBiotech gave a business update via telephone conference call. An audio webcast of the call can be accessed on the Investors relations section of the XBiotech website at [investors.xbiotech.com](http://investors.xbiotech.com). The webcast will be archived for 90 days.

**Item 9.01. Financial Statements and Exhibits.**

- (d) Exhibits.
  - 99.1 Press Release of XBiotech Inc., issued July 28, 2015
-

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**XBIOTECH INC.**

---

(Registrant)

*/s/* **JOHN SIMARD**

---

John Simard

*Chief Executive Officer and President*

**July 29, 2015**

---

(Date)

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release, issued July 28, 2015